Potential conflict of interest: Dr. McHutchison advises Coley Pharmaceuticals Group, Inc. He is on the speakers' bureau of, is a consultant for, advises, and received grants from Schering-Plough. He also received grants from Roche. Dr. Afdhal advises Pharmaceuticals Group, Inc. Dr. Jacobson advises Coley Pharmaceuticals Group, Inc.; Gilead; Vertex; GlobeImmune; Human Genome Science; Novartis; Pfizer; GlaxoSmithKline; Idenix; and Bristol-Myers Squibb. He is a consultant for Gilead, Vertex, Merck, GlobeImmune, Human Genome Science, Novartis, Pfizer, GlaxoSmithKline, Idenix, Bristol-Myers Squibb, Intermune, Schering-Plough, and Valeant. He is on the speakers' bureau of Gilead, GlobeImmune, Idenix, Bristol-Myers Squibb, and Schering-Plough. He also received grants from Gilead, Vertex, GlobeImmune, Novartis, Idenix, Schering-Plough, and Valeant. Dr. Davis owns stock in and holds intellectual property rights to Coley Pharmaceuticals Group, Inc. Dr. Bacon is a consultant for, provides research support to, and is on the speakers' bureau of Schering-Plough. He also provides research support to Roche Laboratories, and Bristol-Myers Squibb. He provides research support to and is on the speakers' bureau of Gilead Sciences and Axcan Pharmaceuticals. He provides research support to and advises GlaxoSmithKline and Novartis. He provides research support to and is a consultant for ISIS, Coley Pharmaceuticals Group Inc., and Valeant.
Article first published online: 10 OCT 2007
Copyright © 2007 American Association for the Study of Liver Diseases
Volume 46, Issue 5, pages 1341–1349, November 2007
How to Cite
McHutchison, J. G., Bacon, B. R., Gordon, S. C., Lawitz, E., Shiffman, M., Afdhal, N. H., Jacobson, I. M., Muir, A., Al-Adhami, M., Morris, M. L., Lekstrom-Himes, J. A., Efler, S. M. and Davis, H. L. (2007), Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology, 46: 1341–1349. doi: 10.1002/hep.21773
All investigations belong to ALT and the study has been conducted by this group since inception.
- Issue published online: 29 OCT 2007
- Article first published online: 10 OCT 2007
- Manuscript Accepted: 12 APR 2007
- Manuscript Received: 12 FEB 2007
- 10CPG 10101 (ACTILON™) oligodeoxynucleotide TLR9 agonist: pharmacokinetics and pharmacodynamics in normal volunteers. In: The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Abstracts. Washington, DC: American Society for Microbiology; 2004: 463–464., , , , , , et al.
- 11Immunophenotyping profile of CPG 10101 (ACTILON™), a new TLR9 agonist antiviral for hepatitis C. HEPATOLOGY 2005; 42(Suppl 1): 539A., , , , , , et al.
- 20Identification of a new class of CpG oligonucleotides capable of inducing both B cell proliferation and high IFN-alpha secretion from PBMC of HCV chronic carriers. Antivir Ther 2002; 7: L115., , , , , , et al.
- 21Safety, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of CPG 10101 (ACTILON™), a novel TLR9 agonist: comparison in normal volunteers and HCV infected individuals. Gastroenterology 2005; 128: A–696., , , , , , et al.